Gestational hypertension nursing: BP thresholds, preeclampsia risk, and NCLEX tips

LS
By Lindsay Smith, AGPCNP
Updated October 7, 2026

Reviewed for clinical accuracy · Methodology: NIH, NCBI, AANP guidelines

Gestational hypertension is the most common hypertensive disorder of pregnancy. Older clinical series put it at 6–17% of nulliparous and 2–4% of multiparous pregnancies, and US birth-certificate data show the problem growing: hypertension diagnosed during pregnancy (a category that combines gestational hypertension and preeclampsia) was recorded for 10.4% of mothers giving birth in 2024, up 73% from 6.0% in 2016. Despite being defined by the absence of the most dangerous features seen in preeclampsia, it is far from benign: up to half of all women with gestational hypertension eventually develop proteinuria or end-organ dysfunction meeting the criteria for preeclampsia, and that progression is more likely when the hypertension is diagnosed before 32 weeks. Severe-range blood pressures carry the same acute risk of stroke and maternal death regardless of the diagnostic label attached to them. For nursing students, gestational hypertension sits at the center of several high-yield NCLEX concepts – distinguishing it from preeclampsia, knowing when blood pressure thresholds mandate intervention, and understanding the postpartum surveillance window that catches late deterioration.

This reference walks through the diagnostic criteria, nursing assessment priorities, antihypertensive management, fetal surveillance strategies, and postpartum considerations. For the full preeclampsia spectrum including HELLP syndrome and eclampsia, see the preeclampsia nursing reference.

Quick reference: hypertensive disorders of pregnancy

Hypertensive disorders of pregnancy – onset, diagnostic criteria, proteinuria, severe features, and management pivot
Condition Onset BP criteria Proteinuria Severe features Management pivot
Gestational hypertension After 20 weeks' gestation SBP ≥140 OR DBP ≥90 on 2 occasions at least 4 h apart Absent Absent Outpatient monitoring if non-severe; deliver at 37 weeks
Preeclampsia without severe features After 20 weeks' gestation SBP ≥140 OR DBP ≥90 on 2 occasions at least 4 h apart Present (≥300 mg/24 h or P:Cr ≥0.3) OR end-organ finding Absent Inpatient or intensive outpatient; MgSO4 not routine (individualized per PB 222); deliver at 37 weeks
Preeclampsia with severe features After 20 weeks' gestation SBP ≥160 OR DBP ≥110 on 2 occasions at least 4 h apart (sooner if antihypertensives are started; severe values persisting ≥15 min are treated) May or may not be present Present (see criteria) Hospitalize; antihypertensives as soon as reasonably possible (within 30–60 min); MgSO4; deliver at ≥34 0/7 weeks after stabilization (earlier if unstable)
Chronic hypertension Before 20 weeks OR pre-pregnancy SBP ≥140 OR DBP ≥90 Absent (unless superimposed preeclampsia develops) Absent at baseline Continue antihypertensives; watch for superimposed preeclampsia
Superimposed preeclampsia Chronic hypertension + new preeclampsia findings after 20 weeks Worsening BP or new severe-range values New-onset OR sudden increase May develop Treat as preeclampsia with severe features if criteria met; earlier delivery

Diagnostic criteria

Gestational hypertension is defined by three positive criteria and three negative criteria. All must be present for the diagnosis to stand.

Positive criteria (all three required):

  • Systolic BP ≥140 mmHg OR diastolic BP ≥90 mmHg
  • Documented on two separate occasions at least 4 hours apart
  • Onset after 20 weeks’ gestation in a woman with previously normal blood pressure

The 4-hour interval requirement exists to exclude transient, positional, or anxiety-related blood pressure elevation. In clinical practice, if a patient presents with BP ≥160/110, you should not wait 4 hours – this is a medical emergency regardless of diagnosis. ACOG Practice Bulletin 222 (reaffirmed 2026) states that acute-onset severe hypertension confirmed as persistent for 15 minutes or more should be treated as soon as reasonably possible, with the literature supporting administration within 30–60 minutes. PB 222 also directs that gestational hypertension presenting with severe-range blood pressures be managed the same way as preeclampsia with severe features.

Negative criteria (all three must be absent):

  • No proteinuria (less than 300 mg in a 24-hour urine collection, protein:creatinine ratio less than 0.3, or urine dipstick less than 2+)
  • No end-organ damage (normal creatinine, platelet count above 100,000/µL, normal liver enzymes, no pulmonary edema, no new-onset headache unresponsive to medication, no visual disturbance)
  • No severe features (as defined by ACOG Practice Bulletin 222, 2020)

The distinction between gestational hypertension and preeclampsia is clinically meaningful because it drives very different management decisions: magnesium sulfate for seizure prophylaxis, inpatient admission intensity, and delivery timing all hinge on whether the patient has progressed beyond gestational hypertension. For a deeper breakdown of how these diagnoses interact with HELLP syndrome, see the obstetric nursing reference.

Resolution: Gestational hypertension resolves by 12 weeks postpartum. If blood pressure remains elevated beyond 12 weeks, the diagnosis is reclassified as chronic hypertension.

Nursing assessment

Blood pressure monitoring

Accurate, consistent blood pressure measurement is the foundation of gestational hypertension management. Several nursing actions directly affect the validity of readings:

  • Use a validated, calibrated cuff appropriate to arm circumference. An undersized cuff falsely elevates readings; an oversized cuff falsely lowers them.
  • Position the patient seated, arm at heart level, after at least 5 minutes of rest. Lateral decubitus position is appropriate for laboring patients; document the position used.
  • For outpatient management, PB 222 recommends serial blood pressure and symptom assessment using a combination of in-clinic and home (ambulatory) readings, with at least one in-clinic visit per week. Document readings, timestamps, and symptoms at each contact.
  • Inpatient patients with non-severe values are typically monitored every 4–6 hours; any reading in the severe range (≥160/110) triggers immediate notification and treatment initiation.

Fetal surveillance

Because gestational hypertension reduces uteroplacental perfusion, fetal wellbeing is monitored alongside maternal blood pressure throughout the pregnancy.

  • Non-stress test (NST): PB 222 recommends an antenatal test one to two times per week for gestational hypertension without severe features; ACOG Committee Opinion 828 lists twice weekly, starting at diagnosis. An NST assesses fetal heart rate reactivity and provides indirect evidence of adequate oxygen delivery. A reactive NST (two accelerations of at least 15 bpm for at least 15 seconds within a 20-minute window) is reassuring.
  • Biophysical profile (BPP): Used as a backup or when NST is non-reactive. Scores breathing movement, body movement, tone, amniotic fluid index, and NST reactivity (total score out of 10). A score of 8–10 is reassuring; 6 is equivocal and usually triggers repeat testing or delivery consideration; 4 or less warrants urgent evaluation.
  • Umbilical artery Doppler: Used selectively when fetal growth restriction is suspected. Absent or reversed end-diastolic flow indicates severe uteroplacental insufficiency and requires immediate escalation.
  • Growth ultrasound: Every 3–4 weeks (PB 222) to monitor for fetal growth restriction, a recognized complication of gestational hypertension due to impaired placental perfusion.
  • Amniotic fluid assessment: At least once weekly (PB 222). Oligohydramnios (AFI less than 5 cm or deepest vertical pocket less than 2 cm) can accompany deteriorating uteroplacental function.

Laboratory surveillance

The primary nursing concern when monitoring labs in a patient with gestational hypertension is detecting the laboratory shift that signals progression to preeclampsia. PB 222 recommends weekly platelet count, serum creatinine, and liver enzymes, plus weekly assessment of proteinuria in gestational hypertension, repeated sooner if progression is a concern. The labs to track include:

  • CBC: Platelets below 100,000/µL signals HELLP syndrome territory and reclassification to preeclampsia with severe features. Hemoconcentration (rising hematocrit) may reflect reduced plasma volume.
  • Comprehensive metabolic panel (CMP): Creatinine above 1.1 mg/dL or doubling of baseline is a severe feature. AST/ALT elevation above twice the upper limit of normal indicates hepatic involvement.
  • Liver function tests (LFTs): Epigastric or right upper quadrant pain should always prompt LFT review – this is a symptom of subcapsular hepatic hemorrhage in HELLP syndrome.
  • Uric acid: Not part of the ACOG diagnostic criteria. Uric acid often rises in preeclampsia and some units still track it, but PB 222 notes limited evidence that it predicts maternal or fetal outcome, so a trend is a prompt for closer surveillance rather than a basis for reclassifying the diagnosis.
  • 24-hour urine protein or spot protein:creatinine ratio: A spot P:Cr ratio of 0.3 or greater is diagnostic of proteinuria sufficient to reclassify the patient as having preeclampsia.

Report immediately to the provider:

  • Any BP reading ≥160/110 mmHg
  • New headache unresponsive to acetaminophen
  • Visual disturbances (blurred vision, scotoma, photophobia)
  • Epigastric or RUQ pain
  • Sudden facial or hand edema
  • Decreased or absent fetal movement
  • Platelet count below 150,000/µL or falling trend
  • Any proteinuria on dipstick (2+ or greater) confirmed on repeat

For information on interpreting lab value trends in complex OB patients, see the nursing lab values cheat sheet.

Management

Blood pressure thresholds and treatment timing

The decision to initiate antihypertensive medication is driven by the severity of the readings, not by the diagnostic label. The threshold for acute treatment is severe-range blood pressure: SBP ≥160 mmHg OR DBP ≥110 mmHg.

ACOG Practice Bulletin 222 directs that acute-onset severe hypertension (persisting 15 minutes or more) be treated as soon as reasonably possible, noting that the literature supports giving antihypertensives within 30–60 minutes. (The older ACOG Committee Opinion 767 on emergent therapy is now listed as withdrawn on acog.org; PB 222 is the current ACOG source.) This is a patient safety priority in pregnancy and postpartum alike: untreated severe-range hypertension is a leading cause of maternal stroke and death in the peripartum period. The nurse’s role is to:

  1. Confirm the reading with a repeat measurement within 15 minutes
  2. Notify the provider immediately
  3. Prepare and administer the ordered antihypertensive promptly
  4. Reassess blood pressure at the interval in the unit protocol for the drug given (commonly 10 minutes after IV labetalol and 20 minutes after IV hydralazine or oral nifedipine)
  5. Document response and notify the provider if BP stays in the severe range; the aim is to bring BP out of the severe range without an abrupt drop that compromises placental perfusion

Non-severe gestational hypertension (SBP 140–159, DBP 90–109) is generally managed with increased surveillance rather than pharmacologic treatment, depending on gestational age and clinical stability. Some providers initiate oral antihypertensives in this range for patients with comorbidities or those approaching term.

Delivery timing

Delivery is the definitive treatment for gestational hypertension. ACOG Practice Bulletin 222 recommends delivery rather than expectant management at or beyond 37 0/7 weeks’ gestation for gestational hypertension without severe features. Earlier delivery may be indicated if the patient develops severe features or her condition deteriorates.

Inpatient versus outpatient management for non-severe gestational hypertension depends on clinical stability, gestational age, and the patient’s ability to comply with home monitoring and return precautions.

Management criteria – inpatient vs outpatient for non-severe gestational hypertension
Criterion Outpatient eligible Inpatient required
BP range Non-severe (SBP 140–159, DBP 90–109) Severe range (SBP ≥160 OR DBP ≥110)
Symptoms Asymptomatic or mild edema Headache, visual changes, epigastric pain, or any severe-feature symptom
Labs Normal (platelets, creatinine, LFTs) Worsening or abnormal (falling platelets, rising creatinine or LFTs)
Fetal status Reactive NST, normal growth, normal AFI Non-reactive NST, growth restriction, oligohydramnios, abnormal Doppler
Gestational age Less than 37 weeks with stable condition 37 weeks or greater (delivery indicated); or any age with instability
Patient compliance Able to perform home BP monitoring and return for scheduled visits Unable to comply with outpatient surveillance requirements

Antihypertensive medications

Antihypertensive medications used in gestational hypertension – route, dosing, and nursing considerations
Medication Class Route / dose Onset Nursing considerations Contraindications / cautions
Labetalol Alpha/beta blocker IV: 10–20 mg, then 20–80 mg every 10–30 min to a maximum cumulative 300 mg, or infusion 1–2 mg/min (PB 222 Table 3). Oral: 200 mg q12h, titrated up to 800 mg q8–12h (max 2,400 mg/day). 1–2 min (IV) Monitor maternal HR – hold if HR less than 60 bpm. Monitor FHR. IV preferred for acute severe hypertension. Administer over 2 minutes. Avoid in asthma, preexisting myocardial disease, decompensated cardiac function, heart block, and bradycardia. One of three agents ACOG lists for acute severe hypertension (with IV hydralazine and oral nifedipine).
Hydralazine Direct vasodilator IV: 5 mg IV or IM, then 5–10 mg IV every 20–40 min to a maximum cumulative 20 mg, or infusion 0.5–10 mg/h (PB 222 Table 3). 10–20 min (IV) Monitor for reflex tachycardia. Maternal hypotension can cause fetal distress – have patient in left lateral position. Higher or frequent doses are linked to maternal hypotension, headache, and abnormal fetal heart rate tracings. PB 222 cites a Cochrane review finding no significant efficacy or safety difference between hydralazine, labetalol, and calcium channel blockers. Use with caution in patients with baseline tachycardia. May cause severe maternal hypotension.
Nifedipine (oral) Calcium channel blocker Oral immediate-release: 10–20 mg PO, repeat in 20 min if needed, then 10–20 mg every 2–6 h; max 180 mg/day (PB 222 Table 3). Extended-release: 30–60 mg daily for maintenance. 5–10 min (oral IR) Administer orally only. Sublingual nifedipine is contraindicated – precipitous BP drop causes maternal hypotension and fetal distress. Monitor for headache (vasodilation side effect). Do not chew or crush extended-release tablets. Sublingual route absolutely contraindicated. Concurrent MgSO4 may potentiate neuromuscular blockade – monitor for neurotoxicity (loss of deep tendon reflexes, respiratory depression).
Methyldopa Central alpha-2 agonist Oral: 250–500 mg q6–12h (max 3 g/day). Not used for acute severe hypertension. Hours Used for non-severe, chronic, or maintenance management. Onset too slow for acute severe hypertension. Monitor for sedation and orthostatic hypotension, especially in first days of therapy. Avoid in hepatic disease (associated with hepatotoxicity). Not appropriate for acute severe BP management. Long safety record in pregnancy; historically first-line oral agent for chronic management.

A critical NCLEX and clinical point: sublingual nifedipine is absolutely contraindicated in pregnancy. The sublingual route bypasses first-pass metabolism and delivers nifedipine too rapidly, causing a precipitous drop in maternal blood pressure that severely reduces uteroplacental perfusion and can precipitate fetal distress. The oral route, with its more gradual absorption, achieves effective blood pressure reduction without this risk.

Regarding magnesium sulfate: MgSO4 is a seizure prophylaxis agent. PB 222 recommends it for gestational hypertension or preeclampsia with severe features and for eclampsia; it has no routine role in gestational hypertension without severe features, where it would add toxicity risk without demonstrated benefit. If MgSO4 is started, PB 222 Table 2 gives the levels to know: therapeutic 4–7 mEq/L (5–9 mg/dL), loss of patellar reflexes above 7 mEq/L, respiratory paralysis above 10 mEq/L, and cardiac arrest above 25 mEq/L. This distinction is heavily tested on NCLEX.

Postpartum considerations

Gestational hypertension does not automatically resolve at delivery. The early postpartum period, particularly the first 3–5 days after birth, carries a significant risk of blood pressure worsening as fluid shifts redistribute following delivery. Some patients who had well-controlled blood pressures during pregnancy will develop their highest readings postpartum.

Postpartum monitoring priorities:

  • Monitor blood pressure in hospital (or with equivalent outpatient surveillance) for at least 72 hours postpartum, per the ACOG hypertension task force; assessment frequency follows unit protocol
  • Educate the patient before discharge on severe-range BP symptoms: persistent headache, visual changes, epigastric pain, and significant swelling – and when to return to care
  • ACOG Committee Opinion 736 recommends a blood pressure evaluation no later than 7–10 days postpartum for all patients with hypertensive disorders of pregnancy, and within 72 hours for those with severe hypertension
  • Postpartum oral antihypertensives may be needed even if the patient did not require them antepartum

Resolution timeline:

Gestational hypertension resolves within 12 weeks postpartum in the vast majority of patients. If blood pressure remains elevated beyond 12 weeks, the diagnosis is reclassified as chronic hypertension, and the patient should be referred for ongoing primary care or cardiology follow-up.

Postpartum hemorrhage risk:

Severe hypertension and antihypertensive therapy can interact with uterotonic agents used for postpartum hemorrhage management. Ergotamine derivatives (methylergonovine) are contraindicated in patients with hypertension because they cause vasoconstriction and can precipitate a hypertensive crisis. Oxytocin remains safe and is the first-line uterotonic. For a full review of postpartum hemorrhage management, see the postpartum hemorrhage nursing reference.

Long-term risk:

Women with a history of gestational hypertension have a significantly elevated risk of developing chronic hypertension, cardiovascular disease, and stroke later in life compared to women with normotensive pregnancies; PB 222 notes that gestational hypertension and preeclampsia may be indistinguishable in long-term cardiovascular risk. This is an important counseling point at discharge. The data from long-term studies suggests gestational hypertension functions as a “stress test” that unmasks underlying vascular susceptibility.

NCLEX high-yield tips

1. The three-criteria rule for gestational hypertension

The diagnosis requires: SBP ≥140 OR DBP ≥90, confirmed on two readings at least 4 hours apart, after 20 weeks’ gestation. If any of the three is missing, the diagnosis does not stand. On NCLEX, watch for scenarios that mention only one reading or onset before 20 weeks.

2. Absence findings define the diagnosis

Gestational hypertension is defined as much by what is absent as by what is present. No proteinuria. No end-organ damage. No severe features. The moment any of these appears, the patient has progressed to preeclampsia. NCLEX scenarios will describe a patient with gestational hypertension and then introduce new symptoms – your job is to recognize the progression.

3. Severe-range BP requires treatment within 30–60 minutes regardless of diagnosis

A patient with gestational hypertension who develops BP ≥160/110 has severe-range hypertension. The treatment urgency is identical to preeclampsia with severe features. Do not delay antihypertensive therapy waiting to reclassify the diagnosis. ACOG Practice Bulletin 222 calls for treatment as soon as reasonably possible once severe-range BP persists 15 minutes or more, with the evidence supporting administration within 30–60 minutes.

4. Sublingual nifedipine is absolutely contraindicated

If an NCLEX question presents a nurse preparing to administer sublingual nifedipine to a pregnant patient with hypertension, the answer is to refuse and question the order. The sublingual route causes an uncontrolled precipitous BP drop that can cause fetal distress. Oral nifedipine is appropriate; sublingual is not.

5. Magnesium sulfate is NOT indicated in gestational hypertension without severe features

MgSO4 is for seizure prophylaxis when severe features are present (gestational hypertension or preeclampsia with severe features, per PB 222) and for eclampsia. It is not an antihypertensive, and it has no routine role in gestational hypertension without severe features. NCLEX frequently tests this distinction. If a question asks which intervention is appropriate for stable, non-severe gestational hypertension, MgSO4 is not the correct answer; once severe-range BP or another severe feature appears, it becomes part of the plan.

6. Up to 50% of all gestational hypertension cases eventually progress to preeclampsia

Read this statistic carefully, because it is easy to misstate. ACOG Practice Bulletin 222 attaches the “up to 50%” figure to women with gestational hypertension as a whole, describing eventual development of proteinuria or other end-organ dysfunction – it is not a rate specific to early-onset cases. What early onset changes is the likelihood: progression is more likely when the hypertension is diagnosed before 32 weeks. On NCLEX, a patient diagnosed with gestational hypertension at 28 weeks should be recognized as high-risk for progression, making surveillance questions a priority.

7. Delivery at 37 weeks is the definitive management

For stable gestational hypertension, delivery is recommended at 37 weeks’ gestation. Before 37 weeks, the goal is to prolong the pregnancy with close surveillance (serial home and in-clinic BP checks with at least one clinic visit per week, antenatal testing once or twice weekly, weekly labs, and growth ultrasound every 3–4 weeks). On NCLEX, if asked about the management priority for a patient at 36 weeks with stable gestational hypertension, the answer is continued outpatient surveillance rather than immediate delivery.

8. The postpartum period is a high-risk window

BP worsening in the first 3–5 days after delivery is common and expected in patients with gestational hypertension. Educating the patient about warning signs (headache, visual changes, epigastric pain, swelling) and providing clear return instructions are mandatory nursing actions before discharge.

9. Uric acid is a soft signal, not a diagnostic criterion

Rising uric acid is associated with preeclampsia, but it is not part of the ACOG diagnostic criteria and PB 222 notes limited evidence that it predicts outcome. Document and report an upward trend as a reason for closer surveillance; do not treat it as diagnostic on its own.

10. Persistent hypertension beyond 12 weeks postpartum = chronic hypertension

If blood pressure has not normalized by 12 weeks after delivery, the diagnosis is reclassified as chronic hypertension. NCLEX may test this reclassification timeline. Know it: 12 weeks is the cutoff.

Gestational hypertension sits within a broader OB cluster of conditions that nursing students commonly study together. The conditions that most closely interact with gestational hypertension management include:

  • Preeclampsia nursing reference – covers diagnostic progression from gestational hypertension, HELLP syndrome, MgSO4 management, and eclampsia
  • HELLP syndrome – the laboratory constellation that can develop from gestational hypertension or preeclampsia
  • Obstetric nursing reference – broad OB framework including labor stages, fetal monitoring, and hypertensive disorder overview
  • Gestational diabetes nursing – the other major pregnancy-specific metabolic condition; often co-occurs with gestational hypertension
  • Postpartum hemorrhage nursing – essential postpartum management, including the ergotamine contraindication relevant to hypertensive patients
  • PROM and PPROM nursing – covers preterm rupture of membranes, which may intersect with early-onset gestational hypertension management decisions

References

  1. American College of Obstetricians and Gynecologists. Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2020;135(6):e237–e260. doi:10.1097/AOG.0000000000003891 [Reaffirmed 2026 on acog.org (checked 2026-10-07). Current ACOG source for acute severe hypertension treatment (Table 3), magnesium levels (Table 2), surveillance, and delivery timing.]
  2. Gregory ECW. Trends and characteristics in gestational hypertension: United States, 2016–2024. National Vital Statistics Reports. Vol 75, No 4. Hyattsville, MD: National Center for Health Statistics; July 29, 2026. doi:10.15620/cdc/252456 [Birth-certificate category combining gestational hypertension and preeclampsia: 6.0% of mothers in 2016, 10.4% in 2024. Replaces ACOG Committee Opinion No. 767 (2019), which acog.org now lists as withdrawn.]
  3. Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407–417. doi:10.1056/NEJMoa1404595
  4. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102(1):181–192.
  5. Duley L, Gülmezoglu AM, Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev. 2010;(9):CD002960. doi:10.1002/14651858.CD002960.pub2
  6. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955–960.
  7. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;(2):CD002252.
  8. Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: making sense of pre-eclampsia – two placental causes of preeclampsia? Placenta. 2014;35(Suppl):S20–S25.
  9. ACOG Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122(5):1122–1131. doi:10.1097/01.AOG.0000437382.03963.88
  10. Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97–104.
  11. Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877–1890.
  12. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622. doi:10.1056/NEJMoa1704559
  13. National Institute for Health and Care Excellence. Hypertension in Pregnancy: Diagnosis and Management. NICE Guideline NG133. London: NICE; 2019.
  14. Lowe SA, Bowyer L, Lust K, et al. The SOMANZ guidelines for the management of hypertensive disorders of pregnancy. Aust N Z J Obstet Gynaecol. 2015;55(5):e1–e29.
  15. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22(2):143–148.
  16. American College of Obstetricians and Gynecologists. Indications for outpatient antenatal fetal surveillance. ACOG Committee Opinion No. 828. Obstet Gynecol. 2021;137(6):e177–e197. doi:10.1097/AOG.0000000000004407 [Reaffirmed 2024. Gestational hypertension or preeclampsia without severe features: testing from diagnosis, twice weekly.]
  17. American College of Obstetricians and Gynecologists. Optimizing postpartum care. ACOG Committee Opinion No. 736. Obstet Gynecol. 2018;131(5):e140–e150. doi:10.1097/AOG.0000000000002633 [Reaffirmed 2025. Blood pressure evaluation no later than 7–10 days postpartum for hypertensive disorders of pregnancy; within 72 hours for severe hypertension.]